PE20081482A1 - Capsulas de gelatina que contienen un acido - Google Patents

Capsulas de gelatina que contienen un acido

Info

Publication number
PE20081482A1
PE20081482A1 PE2007001792A PE2007001792A PE20081482A1 PE 20081482 A1 PE20081482 A1 PE 20081482A1 PE 2007001792 A PE2007001792 A PE 2007001792A PE 2007001792 A PE2007001792 A PE 2007001792A PE 20081482 A1 PE20081482 A1 PE 20081482A1
Authority
PE
Peru
Prior art keywords
acid
composition
refers
filling material
gelatin capsule
Prior art date
Application number
PE2007001792A
Other languages
English (en)
Inventor
Isabel Ottinger
Agnes Taillardat
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37890457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081482(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20081482A1 publication Critical patent/PE20081482A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA EN FORMA DE CAPSULA DE GELATINA LA CUAL COMPRENDE: a) UNA CUBIERTA DE CAPSULA DE GELATINA BLANDA Y b) UN MATERIAL, SEMILIQUIDO O LIQUIDO COMO MICROEMULSION, DE RELLENO; EL CUAL CONTIENE ENTRE 0.01% AL 20% DE UN ACIDO, SELECCIONADO DE ACIDO FUMARICO, ACIDO FOSFORICO, ACIDO MALICO, ACIDO ASCORBICO, ENTRE OTROS, EN EL QUE DICHO ACIDO MIGRA DESDE EL MATERIAL DE RELLENO HACIA LA CUBIERTA DE CAPSULA E INHIBE LA FORMACION DE PELICULA; EL AGENTE ACTIVO PUEDE ESTAR PRESENTE EN HASTA UN 20% DEL PESO TOTAL DE LA COMPOSICION. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION. DICHA COMPOSICION CONTIENE PREFERENTEMENTE 7-TERBUTOXI-IMINO-METIL-CAMPTOTECINA QUE ES UN INHIBIDOR DE TOPOISOMERASA I, UTIL EN EL TRATAMIENTO DE CANCER
PE2007001792A 2006-12-20 2007-12-14 Capsulas de gelatina que contienen un acido PE20081482A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06126698 2006-12-20

Publications (1)

Publication Number Publication Date
PE20081482A1 true PE20081482A1 (es) 2008-12-23

Family

ID=37890457

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001792A PE20081482A1 (es) 2006-12-20 2007-12-14 Capsulas de gelatina que contienen un acido

Country Status (15)

Country Link
US (1) US20100068265A1 (es)
EP (1) EP2120889A1 (es)
JP (1) JP2010513351A (es)
KR (1) KR20090094373A (es)
CN (1) CN101563072A (es)
AR (1) AR064419A1 (es)
AU (1) AU2007334856A1 (es)
BR (1) BRPI0720489A2 (es)
CA (1) CA2672400A1 (es)
CL (1) CL2007003698A1 (es)
MX (1) MX2009006735A (es)
PE (1) PE20081482A1 (es)
TW (1) TW200833375A (es)
UY (1) UY30810A1 (es)
WO (1) WO2008074479A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012002464A1 (ja) * 2010-06-30 2012-01-05 持田製薬株式会社 ω３脂肪酸の配合製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60239418A (ja) * 1984-05-15 1985-11-28 Nippon Kayaku Co Ltd エトポシド軟カプセル製剤
DE4001622A1 (de) * 1990-01-20 1991-07-25 Thomae Gmbh Dr K Orale arzneimittelformen von pimobendan
US5620704A (en) * 1994-11-07 1997-04-15 Warner-Lambert Company Process for stabilizing gelatin products
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
WO1997033568A1 (en) * 1996-03-12 1997-09-18 Novartis Ag Filled gelatin capsules having a reduced degree of cross-linking
US6228894B1 (en) * 1998-04-17 2001-05-08 Enhanced Derm Technologies, Inc. Softgel-compatible composition containing retinol
ES2302926T5 (es) * 2002-04-25 2012-08-23 Banner Pharmacaps, Inc. Cápsula blanda masticable
AU2003240536B2 (en) * 2002-06-05 2007-11-15 Ivax Pharmaceuticals, S.R.O. Reduction of gelatin cross-linking

Also Published As

Publication number Publication date
UY30810A1 (es) 2008-07-31
CN101563072A (zh) 2009-10-21
EP2120889A1 (en) 2009-11-25
AU2007334856A1 (en) 2008-06-26
WO2008074479A1 (en) 2008-06-26
TW200833375A (en) 2008-08-16
AR064419A1 (es) 2009-04-01
CL2007003698A1 (es) 2008-07-18
BRPI0720489A2 (pt) 2014-02-04
KR20090094373A (ko) 2009-09-04
US20100068265A1 (en) 2010-03-18
JP2010513351A (ja) 2010-04-30
MX2009006735A (es) 2009-06-30
CA2672400A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
CO6290641A2 (es) Preparacion de capsula que contiene los ingredientes farmaceuticamente activos liquidos y solidos, la cual presenta exelentes propiedades de los ingredientes farmaceuticamente activos
DOP2017000190A (es) Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas
PE20120923A1 (es) Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo
CL2012000290A1 (es) Composición antitranspirante o desodorante que comprende i) un activo antitranspirante o desodorante, ii) un portador líquido para el activo antitranspirante o desodorante y iii) una fragancia; un producto que comprende la composición y un método para ocultar el mal olor corporal durante un período de tiempo prolongado.
AR049137A1 (es) Formulacion de irinotecan en vesicula cerrada, para el tratamiento del cancer
PE20071310A1 (es) Formulaciones liquidas de fenilefrina
NZ590291A (en) Pharmaceutical compositions for treatment of parkinson's disease
PE20080374A1 (es) Composiciones farmaceuticas de ropinirol
AR045906A1 (es) Composicion farmaceutica para mejorar la solubilidad de farmacos hidrofobicos
DOP2012000217A (es) Pastillas de gelatina blanda con nicotina
AR063362A1 (es) Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada
PE20081311A1 (es) Metodos que usan 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidin-2,6-diona para el tratamiento de linfomas de las celulas del manto
BRPI0707334B8 (pt) formulação de cápsula de gelatina mole de um composto 15-ceto-prostaglandina e método para estabilização do um composto 15-cetoprostaglandina
ES2720954T3 (es) Formulaciones estabilizadas de estatina
BRPI0416650A (pt) composição de lipossoma estável para a aplicação de um agente farmacêutico, composição de lipossoma estéril e estável para a aplicação de um agente farmacêutico método para a produção de uma composição de lipossoma estável para a aplicação de um agente farmacêutico, composição farmacêutica, uso de uma composição de lipossoma, dispositivo para conter uma composição de lipossoma estável, kit para a aplicação de um agente farmacêutico a um paciente, método para aumentar a estabilidade de composições de lipossomas, método para a identificação de uma composição de lipossoma estável na fase, composição de lipossoma e composição de lipossoma estável na fase
AR088918A1 (es) Composiciones antitranspirantes anhidras
ES2897981T3 (es) Composición de dos componentes que comprende ácido acetilsalicílico
SI3060203T1 (en) A effervescent tablet containing a high level of aspirin
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.
PE20060639A1 (es) Composicion farmaceutica en forma de comprimido de residencia gastrica que contiene un principio activo
PE20070711A1 (es) Derivados de piperazina utiles como antagonistas de ccr5
PE20081443A1 (es) Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas
PE20081482A1 (es) Capsulas de gelatina que contienen un acido
MX2016000605A (es) Composiciones y dispositivos para atomizador antitranspirante.
CO2021015117A2 (es) Composición de naproxeno en cápsula blanda miniatura

Legal Events

Date Code Title Description
FD Application declared void or lapsed